Latest news with #VERV
Reuters
10 hours ago
- Business
- Reuters
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
June 16 (Reuters) - Eli Lilly (LLY.N), opens new tab is in advanced talks to acquire gene editing startup Verve Therapeutics (VERV.O), opens new tab for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter. Reuters could not immediately verify the report.
Yahoo
14-05-2025
- Business
- Yahoo
Verve Therapeutics: Q1 Earnings Snapshot
BOSTON (AP) — BOSTON (AP) — Verve Therapeutics Inc. (VERV) on Wednesday reported a loss of $31 million in its first quarter. The Boston-based company said it had a loss of 35 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 71 cents per share. The biotechnology firm posted revenue of $33 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $7.1 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on VERV at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
27-02-2025
- Business
- Washington Post
Verve Therapeutics: Q4 Earnings Snapshot
BOSTON — BOSTON — Verve Therapeutics Inc. (VERV) on Thursday reported a loss of $50 million in its fourth quarter. The Boston-based company said it had a loss of 58 cents per share. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 72 cents per share.
